HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CF PHARMTECH

15.130

-0.070-0.46%

Volume:2.03M

Turnover:30.81M

Market Cap:6.54B

PE:2.29K

High:15.340

Open:15.250

Low:15.120

Close:15.200

52wk High:48.800

52wk Low:14.820

Shares:432.00M

HK Float Shares:323.00M

Volume Ratio:1.24

T/O Rate:0.63%

Dividend:- -

Dividend Rate:- -

EPS(LYR):0.007

ROE:0.21%

ROA:-0.83%

PB:3.82

PE(LYR):2,292.42

PS:12.96

Loading ...

Overview Company News Filings

CF PharmTech board to review FY2025 annual results and final dividend proposal

Hong Kong Market Midday Review: Hang Seng Index Dips 0.17% While AI Model Concept Stocks Climb Against Trend

CF PHARMTECH (02652) Surges Over 21% in Intraday Trading as Advanced Respiratory Pipeline Accelerates Towards Harvest Phase

CF Pharmtech IND application for ICF001 accepted by China’s NMPA

Major Milestone CF Pharmtech, Inc. 2652.HK Announces Ind Acceptance for Pah New Drug With a Globally Innovative Improved Mechanism, Marking Another Milestone for Its Precision Drug Delivery Platform

THOMSON REUTERS

BUZZ-CF PharmTech jumps most on record on new hypertension drug application

CF PHARMTECH (02652) Surges Over 17% as IND for Novel Pulmonary Hypertension Drug is Accepted

CF PHARMTECH (02652): NMPA Accepts IND Application for Inhalation-Powder Candidate ICF001

Bulletin Express

CF PHARMTECH (02652) Receives NMPA Acceptance for IND Application of Self-Developed Inhalation Powder ICF001

CF PharmTech says NMPA accepts IND application for ICF001 inhalation powder

CF Pharmtech Inc - Nmpa Accepts Ind Application for ICF001 Inhalation Powder

THOMSON REUTERS

Global Reformulation Breakthrough! CF PHARMTECH's Pulmonary Hypertension Drug IND Accepted

Hong Kong Market Announcement Highlights | Mengniu Dairy Projects Annual Attributable Profit of Approximately RMB 1.4 to 1.6 Billion

CF PHARMTECH (02652) Receives CTA Approval for Combined Nasal Spray Targeting Allergic Rhinitis

Bulletin Express

CF PHARMTECH (02652) Receives NMPA Approval for Clinical Trial Application of Olopatadine Mometasone Nasal Spray

CF Pharmtech Inc - Approval of Clinical Trial Application for Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray by Nmpa

THOMSON REUTERS

CF PharmTech wins NMPA clinical trial approval for olopatadine-mometasone nasal spray

CF PHARMTECH (02652) Included in Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

CF PHARMTECH (02652) Included in Shanghai-HK and Shenzhen-HK Stock Connect

Bulletin Express

CF PharmTech (02652) Announces Monthly Return for February 2026

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/02652/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02652","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02652\",,,,,undefined,":{"symbol":"02652","market":"HK","secType":"STK","nameCN":"CF PHARMTECH","latestPrice":15.13,"timestamp":1787544300006,"preClose":15.2,"halted":0,"volume":2026100,"delay":0,"changeRate":-0.004605263157894639,"floatShares":323000000,"shares":432000000,"eps":0.0066,"marketStatus":"Noon Closed","change":-0.07,"latestTime":"08-24 12:05:00","open":15.25,"high":15.34,"low":15.12,"amount":30814605,"amplitude":0.014474,"askPrice":15.13,"askSize":7200,"bidPrice":15.12,"bidSize":16100,"shortable":3,"etf":0,"ttmEps":0.006,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787547600000},"marketStatusCode":3,"adr":0,"listingDate":1759852800000,"exchange":"SEHK","adjPreClose":15.2,"openAndCloseTimeList":[[1787535000000,1787544000000],[1787547600000,1787558400000]],"volumeRatio":1.244471,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02652\",,,,,undefined,":{"symbol":"02652","floatShares":323000000,"roa":"-0.83%","roe":"0.21%","lyrEps":0.0066,"volumeRatio":1.244471,"shares":432000000,"dividePrice":0,"high":15.34,"amplitude":0.014474,"preClose":15.2,"low":15.12,"week52Low":14.82,"pbRate":"3.82","psRate":"12.96","week52High":48.8,"institutionHeld":0,"latestPrice":15.13,"committee":0.381974,"eps":0.0066,"divideRate":0,"volume":2026100,"delay":0,"ttmEps":0.006,"open":15.25,"prevYearClose":35,"prevWeekClose":15.2,"prevMonthClose":19.87,"prevQuarterClose":21,"fiveDayClose":16.73,"twentyDayClose":15.98,"sixtyDayClose":20.2,"earningDate":1788105600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02652\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"02652","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-30","symbol":"02652","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02652\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02652\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02652\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02652","date":"2026-08-21","current":2533.333333,"percent":0.556604,"low":-293.764894,"twenty":418.883405,"median":491.347467,"eighty":2826.107192,"high":3595.964728,"avg":1473.150348,"sd":1193.496335,"marketCap":6240837082},"quantilePoints":[{"date":"2025-10-10","current":420.512992,"twenty":-8.053739,"median":420.512992,"eighty":438.465035,"marketCap":12738371726},{"date":"2025-10-17","current":400.969089,"twenty":380.917252,"median":393.18793,"eighty":412.695431,"marketCap":12136883281},{"date":"2025-10-24","current":382.04749,"twenty":383.954109,"median":395.798507,"eighty":407.879105,"marketCap":11568353106},{"date":"2025-10-31","current":411.638127,"twenty":385.87135,"median":395.798507,"eighty":410.009732,"marketCap":12482945126},{"date":"2025-11-07","current":380.629431,"twenty":385.87135,"median":397.412529,"eighty":410.009732,"marketCap":11535394836},{"date":"2025-11-14","current":413.442652,"twenty":386.82146,"median":399.24986,"eighty":411.625005,"marketCap":12565340803},{"date":"2025-11-21","current":474.663516,"twenty":387.596392,"median":401.654037,"eighty":419.1227,"marketCap":14419243545},{"date":"2025-11-28","current":513.213561,"twenty":390.697015,"median":408.734506,"eighty":451.19497,"marketCap":15646939138},{"date":"2025-12-05","current":509.365027,"twenty":391.797785,"median":411.605323,"eighty":487.699676,"marketCap":15556303893},{"date":"2025-12-12","current":478.26383,"twenty":394.588712,"median":413.442652,"eighty":485.541496,"marketCap":14633472306},{"date":"2025-12-19","current":468.273561,"twenty":396.041553,"median":429.606948,"eighty":482.974301,"marketCap":14361566570},{"date":"2025-12-24","current":469.497744,"twenty":396.770692,"median":439.211078,"eighty":482.563912,"marketCap":14443962248},{"date":"2026-01-02","current":452.984556,"twenty":397.492287,"median":451.385447,"eighty":481.570975,"marketCap":13990786022},{"date":"2026-01-09","current":417.797013,"twenty":398.674444,"median":438.955991,"eighty":480.057858,"marketCap":12936121351},{"date":"2026-01-16","current":442.060347,"twenty":399.985866,"median":432.778937,"eighty":478.730146,"marketCap":13731858722},{"date":"2026-01-23","current":466.639698,"twenty":400.772068,"median":439.902936,"eighty":477.371374,"marketCap":14481468286},{"date":"2026-01-30","current":480.840623,"twenty":401.791027,"median":446.916666,"eighty":477.757159,"marketCap":14990389486},{"date":"2026-02-06","current":464.022312,"twenty":403.190746,"median":452.185001,"eighty":477.033593,"marketCap":14502764350},{"date":"2026-02-13","current":452.173894,"twenty":406.744138,"median":454.320794,"eighty":475.6532,"marketCap":14213623359},{"date":"2026-02-20","current":472.094804,"twenty":408.734506,"median":454.916554,"eighty":476.776403,"marketCap":14818441932},{"date":"2026-02-27","current":505.751529,"twenty":411.273773,"median":459.838493,"eighty":479.42962,"marketCap":16048983093},{"date":"2026-03-06","current":445.246344,"twenty":411.572519,"median":460.887466,"eighty":481.94993,"marketCap":14015073071},{"date":"2026-03-13","current":299.287031,"twenty":402.338985,"median":457.528006,"eighty":481.000215,"marketCap":9464083401},{"date":"2026-03-20","current":315.053976,"twenty":397.81132,"median":454.320794,"eighty":480.840623,"marketCap":9924943114},{"date":"2026-03-27","current":299.095644,"twenty":391.175665,"median":451.779671,"eighty":479.42962,"marketCap":9398246299},{"date":"2026-04-02","current":3318.248683,"twenty":389.832113,"median":451.779671,"eighty":480.872541,"marketCap":9381570423},{"date":"2026-04-10","current":3321.445916,"twenty":390.816678,"median":452.984556,"eighty":482.236241,"marketCap":9463036901},{"date":"2026-04-17","current":3317.060015,"twenty":392.419904,"median":455.282385,"eighty":483.410603,"marketCap":9454509433},{"date":"2026-04-24","current":2996.4431,"twenty":394.891161,"median":460.26919,"eighty":490.336167,"marketCap":8541149514},{"date":"2026-04-30","current":3202.871531,"twenty":396.041553,"median":462.144769,"eighty":499.979081,"marketCap":9131900891},{"date":"2026-05-08","current":3148.404437,"twenty":397.173254,"median":463.774025,"eighty":508.169798,"marketCap":9007763175},{"date":"2026-05-15","current":2973.181714,"twenty":398.099028,"median":464.50673,"eighty":512.854422,"marketCap":8528814526},{"date":"2026-05-22","current":2811.882705,"twenty":399.495195,"median":466.720409,"eighty":2921.871357,"marketCap":8047680823},{"date":"2026-05-29","current":3180.044455,"twenty":400.476536,"median":467.247998,"eighty":2926.706614,"marketCap":9133017429},{"date":"2026-06-05","current":2895.334441,"twenty":400.969089,"median":468.273561,"eighty":2926.706614,"marketCap":8327404730},{"date":"2026-06-12","current":2591.262092,"twenty":402.338985,"median":469.314298,"eighty":2919.612019,"marketCap":7447807192},{"date":"2026-06-18","current":2679.987141,"twenty":403.474666,"median":471.144686,"eighty":2910.923271,"marketCap":7719084937},{"date":"2026-06-26","current":2653.65777,"twenty":407.739322,"median":472.774581,"eighty":2903.774482,"marketCap":7608107678},{"date":"2026-07-03","current":2674.595079,"twenty":410.258066,"median":474.904398,"eighty":2905.018632,"marketCap":7673871980},{"date":"2026-07-10","current":2510.065653,"twenty":411.453021,"median":477.841604,"eighty":2898.212797,"marketCap":7192970522},{"date":"2026-07-17","current":2212.458756,"twenty":411.611884,"median":479.42962,"eighty":2892.703479,"marketCap":6362696210},{"date":"2026-07-24","current":2249.530522,"twenty":411.787912,"median":481.475073,"eighty":2888.435745,"marketCap":6470762659},{"date":"2026-07-31","current":2830.800739,"twenty":412.509722,"median":482.52515,"eighty":2884.270453,"marketCap":8158252159},{"date":"2026-08-07","current":2582.169982,"twenty":413.490204,"median":483.399827,"eighty":2872.355071,"marketCap":7456157987},{"date":"2026-08-14","current":2399.972298,"twenty":415.255724,"median":487.118208,"eighty":2848.370255,"marketCap":6938825440},{"date":"2026-08-21","current":2153.795127,"twenty":418.883405,"median":491.347467,"eighty":2826.107192,"marketCap":6240837082}],"updateTime":1787510907906},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02652\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620355502","title":"CF PharmTech board to review FY2025 annual results and final dividend proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2620355502","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620355502?lang=en_us&edition=fundamental","pubTime":"2026-03-18 16:31","pubTimestamp":1773822665,"startTime":"0","endTime":"0","summary":"CF Pharmtech’s board will meet on March 30, 2026 to consider and approve the group’s annual results for the year ended December 31, 2025. The board will also consider a recommendation on a final dividend at the March 30, 2026 meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLcfs3QB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181630658","title":"Hong Kong Market Midday Review: Hang Seng Index Dips 0.17% While AI Model Concept Stocks Climb Against Trend","url":"https://stock-news.laohu8.com/highlight/detail?id=1181630658","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181630658?lang=en_us&edition=fundamental","pubTime":"2026-03-18 12:11","pubTimestamp":1773807063,"startTime":"0","endTime":"0","summary":"The Hang Seng Index declined by 0.17%, shedding 43 points to reach 25,824 points in morning trading. The Hang Seng Tech Index dropped by 0.81%. Morning session turnover on the Hong Kong market...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0051755006.USD","LU0140636845.USD","LU0572944931.SGD","LU0326950275.SGD","02057","LU1770034418.SGD","ZTO","HSImain","LU0244354667.USD","BK1615","LU0359202008.SGD","LU0307460666.USD","HSTECH","BK1117","BK4585","BK1575","BK4588","LU2097828805.USD","LU2097828631.EUR","LU1720050803.USD","00100","LU1023057109.AUD","LU1794554557.SGD","09698","LU0348767384.USD","LU2097828714.EUR","LU0210526637.USD","LU0327786744.USD","01138","03858","HTImain","LU0588546209.SGD","603986","MCHmain","LU2097828557.USD","LU0348766576.USD","600026","LU0359201885.HKD","LU1251922891.USD","06088","06809","HSI","02513","BK1591","HHImain","LU0463099449.HKD","02652","KSTmain","81024","LU0211977185.USD","BK1590","BK1095","02833","00667","513600","BK1608","688008","LU0593848301.USD","LU0456827905.SGD","03986","LU1188198961.HKD","LU1719994722.HKD","LU0359201612.USD","LU1303224171.USD","BK1610","LU2097828474.EUR","GDS"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1105666137","title":"CF PHARMTECH (02652) Surges Over 21% in Intraday Trading as Advanced Respiratory Pipeline Accelerates Towards Harvest Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=1105666137","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105666137?lang=en_us&edition=fundamental","pubTime":"2026-03-18 10:14","pubTimestamp":1773800059,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) saw its shares rise more than 21% during the morning session. At the time of writing, the stock was up 14.54%, trading at HK$28.2, with a turnover of HK$81.96 million. The surge...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK4588","02652","BK1191","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619884451","title":"CF Pharmtech IND application for ICF001 accepted by China’s NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2619884451","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619884451?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:09","pubTimestamp":1773655750,"startTime":"0","endTime":"0","summary":"China’s NMPA accepted CF Pharmtech’s IND application for ICF001, an inhaled powder drug candidate. The regulatory review covers treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL6yd8t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619459042","title":"Major Milestone CF Pharmtech, Inc. 2652.HK Announces Ind Acceptance for Pah New Drug With a Globally Innovative Improved Mechanism, Marking Another Milestone for Its Precision Drug Delivery Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2619459042","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619459042?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:08","pubTimestamp":1773655738,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUC1KMF2D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619802434","title":"BUZZ-CF PharmTech jumps most on record on new hypertension drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2619802434","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619802434?lang=en_us&edition=fundamental","pubTime":"2026-03-16 10:36","pubTimestamp":1773628582,"startTime":"0","endTime":"0","summary":"BUZZ-CF PharmTech jumps most on record on new hypertension drug application** Shares of China-based inhalation technologies and drugs developer CF PharmTech Inc 2652.HK soar 37.6% to HK$31.64; on course for the biggest one-day pct gain since debut on October 8** Stock hits the highest since March 10** Company said China's National Medical Products Administration had accepted investigational new drug  application for its inhalation powder candidate ICF001 to treat pulmonary hypertension and related pulmonary diseases** ICF001 possesses broad potential to expand into larger patient populations, such as those with pulmonary fibrosis associated with interstitial lung disease, in the future - Co** YTD, stock down 12.9%, while Hang Seng Biotech Index .HSBIO up 0.3%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL1N40402C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136164556","title":"CF PHARMTECH (02652) Surges Over 17% as IND for Novel Pulmonary Hypertension Drug is Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=1136164556","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136164556?lang=en_us&edition=fundamental","pubTime":"2026-03-16 10:08","pubTimestamp":1773626908,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) saw its shares rise more than 17%. At the time of writing, the stock was up 16.43%, trading at HK$26.78, with a turnover of HK$12.2058 million. On the news front, on March 13, CF...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0208291251.USD","BK1191","LU0256863902.USD","LU1989772923.USD","LU0211331839.USD","02652","LU0417517546.SGD","BK4588","BK4161","PH","LU0320765489.SGD","LU0256863811.USD","IND","LU2264538146.SGD","BK4585","BK4580","VXUS","LU1988902786.USD","LU1989772840.SGD","LU0070302665.USD","LU1064131342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120165890","title":"CF PHARMTECH (02652): NMPA Accepts IND Application for Inhalation-Powder Candidate ICF001","url":"https://stock-news.laohu8.com/highlight/detail?id=1120165890","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120165890?lang=en_us&edition=fundamental","pubTime":"2026-03-13 21:21","pubTimestamp":1773408119,"startTime":"0","endTime":"0","summary":"Hong Kong – CF PharmTech, Inc. (stock code: 02652) announced that the National Medical Products Administration (NMPA) has formally accepted the Investigational New Drug (IND) application for its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126576438","title":"CF PHARMTECH (02652) Receives NMPA Acceptance for IND Application of Self-Developed Inhalation Powder ICF001","url":"https://stock-news.laohu8.com/highlight/detail?id=1126576438","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126576438?lang=en_us&edition=fundamental","pubTime":"2026-03-13 21:06","pubTimestamp":1773407187,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) has announced that the Investigational New Drug (IND) application for its self-developed inhalation powder candidate, ICF001, has been accepted by the National Medical Products...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619197090","title":"CF PharmTech says NMPA accepts IND application for ICF001 inhalation powder","url":"https://stock-news.laohu8.com/highlight/detail?id=2619197090","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619197090?lang=en_us&edition=fundamental","pubTime":"2026-03-13 21:04","pubTimestamp":1773407089,"startTime":"0","endTime":"0","summary":"CF Pharmtech said China’s National Medical Products Administration accepted its investigational new drug application for ICF001, an inhalation powder candidate. The filing is for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The applicant is CF Pharmtech Guangzhou, a subsidiary of the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDLbrycGY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619197455","title":"CF Pharmtech Inc - Nmpa Accepts Ind Application for ICF001 Inhalation Powder","url":"https://stock-news.laohu8.com/highlight/detail?id=2619197455","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619197455?lang=en_us&edition=fundamental","pubTime":"2026-03-13 21:00","pubTimestamp":1773406817,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN4010IJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136781619","title":"Global Reformulation Breakthrough! CF PHARMTECH's Pulmonary Hypertension Drug IND Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=1136781619","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136781619?lang=en_us&edition=fundamental","pubTime":"2026-03-13 13:48","pubTimestamp":1773380909,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) announced on March 13 that the Investigational New Drug (IND) application for its self-developed inhaled powder ICF001 has been formally accepted by China's National Medical...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652","BK1191","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112141928","title":"Hong Kong Market Announcement Highlights | Mengniu Dairy Projects Annual Attributable Profit of Approximately RMB 1.4 to 1.6 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1112141928","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112141928?lang=en_us&edition=fundamental","pubTime":"2026-03-09 09:17","pubTimestamp":1773019041,"startTime":"0","endTime":"0","summary":"Significant Corporate Developments: Hengrui Pharmaceuticals (01276) announced that its adebelisib injection has received a drug clinical trial approval notice. Anjoy Foods (02648) plans to inject an...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348788117.USD","LU0651946864.USD","LU1048588211.SGD","LU1023057109.AUD","BK1589","IE0009570106.USD","LU0048580855.USD","LU0251143458.SGD","SG9999002828.SGD","HK0000306701.USD","LU0228659784.USD","LU0029875118.USD","LU1051768304.USD","IE0008369823.USD","LU0823426308.USD","LU0650527681.SGD","LU1102505929.USD","LU0359201885.HKD","LU0672654166.SGD","LU0307460666.USD","LU0326950275.SGD","IE00B29SXG58.USD","LU0259732245.USD","LU0370786039.SGD","BK1521","IE00B031J352.USD","LU1115378108.SGD","LU0320764755.SGD","VXUS","LU0359202008.SGD","BK1553","BK1237","LU0385154629.USD","LU1439103000.SGD","IE00B031HY20.USD","LU1515016050.SGD","LU0543330483.HKD","BK1597","02319","LU2045819591.USD","HK0000320264.USD","IE00B067MR52.USD","IE0008368742.USD","02652","LU1102505762.USD","LU0315179316.USD","LU0588546209.SGD","IE00B0169L03.USD","BK4588","IE00B97KM107.HKD","LU0328353924.USD","LU1769817096.USD","LU0163747925.USD","LU0737861699.HKD","IE0031814852.USD","LU0106959298.USD","LU0471298777.SGD","LU0640798160.USD","LU2125910500.SGD","HK0000306685.HKD","HK0000320223.HKD","IE0032834883.USD","LU0228367735.SGD","LU1224709979.USD","LU0072462343.USD","BK1191","LU0211977185.USD","LU0359201612.USD","BK4585","VT","LU0173614495.USD","LU0594300419.USD","LU0823426480.USD","LU0287142896.SGD","LU1769817179.HKD","SG9999011746.SGD","LU0128522157.USD","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162637253","title":"CF PHARMTECH (02652) Receives CTA Approval for Combined Nasal Spray Targeting Allergic Rhinitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1162637253","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162637253?lang=en_us&edition=fundamental","pubTime":"2026-03-09 08:02","pubTimestamp":1773014569,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) received approval from the National Medical Products Administration for a clinical trial application (CTA) concerning a nasal spray that combines olopatadine hydrochloride and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169494763","title":"CF PHARMTECH (02652) Receives NMPA Approval for Clinical Trial Application of Olopatadine Mometasone Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=1169494763","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169494763?lang=en_us&edition=fundamental","pubTime":"2026-03-09 07:50","pubTimestamp":1773013823,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) has announced that the Clinical Trial Application (CTA) for its Olopatadine Mometasone Nasal Spray has been approved by the National Medical Products Administration (NMPA) of...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618569405","title":"CF Pharmtech Inc - Approval of Clinical Trial Application for Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2618569405","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618569405?lang=en_us&edition=fundamental","pubTime":"2026-03-09 07:44","pubTimestamp":1773013496,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260308:nFWN3ZU1HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618037694","title":"CF PharmTech wins NMPA clinical trial approval for olopatadine-mometasone nasal spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2618037694","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618037694?lang=en_us&edition=fundamental","pubTime":"2026-03-09 07:44","pubTimestamp":1773013477,"startTime":"0","endTime":"0","summary":"CF PharmTech said China’s NMPA approved its clinical trial application for an olopatadine hydrochloride and mometasone furoate monohydrate nasal spray. The product is a fixed-dose antihistamine and corticosteroid combination for moderate-to-severe allergic rhinitis in adults and children aged 12 and older. CF PharmTech said it was the first company in China to submit a generic clinical trial application for this product.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260308:nNDL9yY3wg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192634517","title":"CF PHARMTECH (02652) Included in Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=1192634517","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192634517?lang=en_us&edition=fundamental","pubTime":"2026-03-08 18:44","pubTimestamp":1772966656,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) announced that its H shares have been officially included in the list of securities eligible for the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs. This...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","02652","VXUS","BK1191","BK4588","VT","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164337640","title":"CF PHARMTECH (02652) Included in Shanghai-HK and Shenzhen-HK Stock Connect","url":"https://stock-news.laohu8.com/highlight/detail?id=1164337640","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164337640?lang=en_us&edition=fundamental","pubTime":"2026-03-08 18:42","pubTimestamp":1772966562,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) announced that its H shares have been officially included in the list of eligible securities under both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170564489","title":"CF PharmTech (02652) Announces Monthly Return for February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1170564489","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170564489?lang=en_us&edition=fundamental","pubTime":"2026-03-02 16:51","pubTimestamp":1772441506,"startTime":"0","endTime":"0","summary":"CF PharmTech, Inc. reported no change in its total registered share capital for February 2026, maintaining 302.22 million H shares and 109.75 million Domestic Shares at a par value of RMB 1 each,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":7,"totalSize":153,"code":"91000000","status":"200"}]}}